HER2 Support Group Forums - View Single Post - 1000% increase in chemotherapy efficiency with prozac!

Rich66 · 09-30-2009, 09:35 PM

Based on more recent research, overall..doesn't look they increase risk

2005
1: Epidemiology. 2005 Jan;16(1):101-5.

Links
Breast cancer risk among users of antidepressant medications.

GonzÃ¡lez-PÃ©rez A, GarcÃ*a RodrÃ*guez LA.
Centro EspaÃ±ol de InvestigaciÃ³n FarmacoepidemiolÃ³gica (CEIFE), Madrid, Spain. agonzalez@ceife.es
BACKGROUND: Breast cancer is the most common cancer in women. Laboratory studies suggest that antidepressants may promote breast cancer tumor growth. Several epidemiologic studies have evaluated this association with conflicting results. METHODS: We conducted a cohort study with a secondary nested case-control analysis based on the General Practice Research Database. Our goal was to assess the association between the risk of breast cancer and use of serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and other antidepressants. We calculated adjusted estimates controlling for breast cancer risk factors using unconditional logistic regression. RESULTS: A total of 3708 cases of breast cancer were ascertained. Overall, antidepressant use was not associated with an increased risk of breast cancer. Current users of SSRIs had an odds ratio (OR) of 0.98 (95% confidence interval=0.81-1.19), whereas current users of TCAs had an OR of 0.86 (0.73-1.00). When only use for longer than 1 year was considered, the corresponding estimates for SSRIs and TCAs were 0.76 (0.53-1.09) and 0.87 (0.70-1.09), respectively. None of the individual drugs was associated with breast cancer risk. CONCLUSIONS: Use of antidepressants was not associated with an increased risk of breast cancer regardless of duration of use, daily dose, or specific drug being used. These results, together with evidence from prior studies, support the lack of a clinically meaningful association between breast cancer risk and antidepressants.
PMID: 15613952 [PubMed - indexed for MEDLIN

2006
http://www.dslrf.org/breastcancer/co...id=132&cid=598

and

1: Breast Cancer Res Treat. 2006 Jan;95(2):131-40. Epub 2005 Dec 2.

Links
Antidepressant use and breast cancer risk.

Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR.
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. cchien@fhcrc.org
BACKGROUND: Antidepressants are among the most commonly prescribed drugs in the United States. Laboratory studies suggest that because certain antidepressants increase prolactin levels that they may also increase breast cancer risk. However, human studies evaluating use of antidepressants in relation to breast cancer risk have yielded inconsistent results. METHODS: A population-based case-control study consisting of 975 breast cancer cases 65-79 years of age diagnosed from 1997-1999 and 1007 age and residence-matched controls was conducted in western Washington State. Detailed information on antidepressant use was obtained through structured in-person interviews. Logistic regression was performed to analyze the relationship between antidepressant use and breast cancer risk. RESULTS: Overall, there was no association between ever use of antidepressants and breast cancer risk (odds ratio [OR] = 1.2, 95% confidence interval [95% CI]: 0.9-1.6). When evaluated separately, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), and triazolopyridines were each not associated with breast cancer risk. However, risk varied by hormone receptor status. Compared to never users, ever users of SSRIs had elevated risks of progesterone receptor (PR) negative and estrogen receptor (ER) positive/PR-negative breast cancers (OR = 1.8, 95% CI: 1.1-3.6 and OR = 2.0, 95% CI: 1.1-3.8, respectively), but not of tumors with other hormone receptor profiles. CONCLUSIONS: Based on these results and those of previous studies, there is limited evidence that any type of antidepressant use is associated with breast cancer risk overall. SSRIs may elevate risks of PR- and ER+/PR- tumors, though further studies are needed to confirm these associations.
PMID: 16322894 [PubMed - indexed for MEDLINE

1: Expert Rev Neurother. 2006 Sep;6(9):1363-74.

Links
Review of the epidemiological literature on antidepressant use and breast cancer risk.

Coogan PF.
Slone Epidemiology Center, Boston University, MA, USA. pcoogan@bu.edu
Based on evidence that antidepressants increase levels of prolactin and may promote the growth of mammary tumor cells, there has been concern that the use of these drugs may increase the risk of breast cancer. This article reviews the epidemiological evidence on the relationship between breast cancer risk and the use of the selective serotonin reuptake inhibitors, the tricyclic antidepressants and other antidepressants. Overall, the evidence does not support the hypothesis that the use of antidepressants increases the risk of breast cancer. There is a dearth of data on long-term selective serotonin reuptake inhibitor use. Since these drugs are commonly used, it is prudent public health policy to monitor breast cancer incidence among women using this class of drug for long durations.
PMID: 17009923 [PubMed - indexed for MEDLINE

2008
Links
Anti-depressants not linked to increasing risk of cancer.

McCord A.
PMID: 19048675 [PubMed - indexed for MEDLINE]
no abstract available

2009
1: Pharmacoepidemiol Drug Saf. 2009 Jul 21. [Epub ahead of print]

Links
Antidepressant use and colorectal cancer risk.

Coogan PF, Strom BL, Rosenberg L.
Slone Epidemiology Center at Boston University, Boston, MA, USA.
PURPOSE: A previous epidemiologic study reported a 30% reduced risk of colorectal cancer among users of high doses of selective serotonin reuptake inhibitors (SSRIs). We assessed the association of colorectal cancer risk with SSRI and tricyclic antidepressant use in our hospital-based Case Control Surveillance Study. METHODS: For the SSRI analyses, we used data collected on 529 colorectal cancer cases and 1955 hospitalized controls collected from 1995 to 2008. For the tricyclic antidepressant analyses, we used data on 2889 cases and 7122 controls collected from 1976 to 2008. We used multivariable logistic regression analysis to evaluate the association of regular SSRI use and regular tricyclic antidepressant use (daily use for at least 3 continuous months) with colorectal cancer risk. RESULTS: The odds ratio for regular SSRI use was 0.55 (95% CI 0.35-0.88) and it did not differ by duration of use. The odds ratio was 0.47 (95% CI 0.26-0.85) for colon cancer and 0.72 (95% CI 0.37-1.41) for rectal cancer. The odds ratio for regular use of tricyclic antidepressants was 0.77 (95% CI 0.52-1.16) CONCLUSIONS: We found an association of reduced risk of colorectal cancer with regular use of SSRIs. In light of laboratory data indicating that SSRIs may inhibit colon cancer and one previous epidemiologic study that also observed a decreased risk, further investigation of the effect of SSRIs on the risk of colorectal cancer is warranted. Copyright (c) 2009 John Wiley & Sons, Ltd.

09-30-2009, 09:35 PM	#16
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Re: 1000% increase in chemotherapy efficiency with prozac! Based on more recent research, overall..doesn't look they increase risk 2005 1: Epidemiology. 2005 Jan;16(1):101-5. Links Breast cancer risk among users of antidepressant medications. GonzÃ¡lez-PÃ©rez A, *GarcÃa RodrÃguez LA. Centro EspaÃ±ol de InvestigaciÃ³n FarmacoepidemiolÃ³gica (CEIFE), Madrid, Spain. agonzalez@ceife.es BACKGROUND: Breast cancer is the most common cancer in women. Laboratory studies suggest that antidepressants may promote breast cancer tumor growth. Several epidemiologic studies have evaluated this association with conflicting results. METHODS: We conducted a cohort study with a secondary nested case-control analysis based on the General Practice Research Database. Our goal was to assess the association between the risk of breast cancer and use of serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and other antidepressants. We calculated adjusted estimates controlling for breast cancer risk factors using unconditional logistic regression. RESULTS: A total of 3708 cases of breast cancer were ascertained. Overall, antidepressant use was not associated with an increased risk of breast cancer. Current users of SSRIs had an odds ratio (OR) of 0.98 (95% confidence interval=0.81-1.19), whereas current users of TCAs had an OR of 0.86 (0.73-1.00). When only use for longer than 1 year was considered, the corresponding estimates for SSRIs and TCAs were 0.76 (0.53-1.09) and 0.87 (0.70-1.09), respectively. None of the individual drugs was associated with breast cancer risk. CONCLUSIONS: Use of antidepressants was not associated with an increased risk of breast cancer regardless of duration of use, daily dose, or specific drug being used. These results, together with evidence from prior studies, support the lack of a clinically meaningful association between breast cancer risk and antidepressants. PMID: 15613952 [PubMed - indexed for MEDLIN 2006 http://www.dslrf.org/breastcancer/co...id=132&cid=598 and 1: Breast Cancer Res Treat. 2006 Jan;95(2):131-40. Epub 2005 Dec 2. Links Antidepressant use and breast cancer risk.* Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. cchien@fhcrc.org BACKGROUND: Antidepressants are among the most commonly prescribed drugs in the United States. Laboratory studies suggest that because certain antidepressants increase prolactin levels that they may also increase breast cancer risk. However, human studies evaluating use of antidepressants in relation to breast cancer risk have yielded inconsistent results. METHODS: A population-based case-control study consisting of 975 breast cancer cases 65-79 years of age diagnosed from 1997-1999 and 1007 age and residence-matched controls was conducted in western Washington State. Detailed information on antidepressant use was obtained through structured in-person interviews. Logistic regression was performed to analyze the relationship between antidepressant use and breast cancer risk. RESULTS: Overall, there was no association between ever use of antidepressants and breast cancer risk (odds ratio [OR] = 1.2, 95% confidence interval [95% CI]: 0.9-1.6). When evaluated separately, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), and triazolopyridines were each not associated with breast cancer risk. However, risk varied by hormone receptor status. Compared to never users, ever users of SSRIs had elevated risks of progesterone receptor (PR) negative and estrogen receptor (ER) positive/PR-negative breast cancers (OR = 1.8, 95% CI: 1.1-3.6 and OR = 2.0, 95% CI: 1.1-3.8, respectively), but not of tumors with other hormone receptor profiles. CONCLUSIONS: Based on these results and those of previous studies, there is limited evidence that any type of antidepressant use is associated with breast cancer risk overall. SSRIs may elevate risks of PR- and ER+/PR- tumors, though further studies are needed to confirm these associations. PMID: 16322894 [PubMed - indexed for MEDLINE 1: Expert Rev Neurother. 2006 Sep;6(9):1363-74. Links Review of the epidemiological literature on antidepressant use and breast cancer risk. Coogan PF. Slone Epidemiology Center, Boston University, MA, USA. pcoogan@bu.edu Based on evidence that antidepressants increase levels of prolactin and may promote the growth of mammary tumor cells, there has been concern that the use of these drugs may increase the risk of breast cancer. This article reviews the epidemiological evidence on the relationship between breast cancer risk and the use of the selective serotonin reuptake inhibitors, the tricyclic antidepressants and other antidepressants. Overall, the evidence does not support the hypothesis that the use of antidepressants increases the risk of breast cancer. There is a dearth of data on long-term selective serotonin reuptake inhibitor use. Since these drugs are commonly used, it is prudent public health policy to monitor breast cancer incidence among women using this class of drug for long durations. PMID: 17009923 [PubMed - indexed for MEDLINE 2008 Links Anti-depressants not linked to increasing risk of cancer. McCord A. PMID: 19048675 [PubMed - indexed for MEDLINE] no abstract available 2009 1: Pharmacoepidemiol Drug Saf. 2009 Jul 21. [Epub ahead of print] Links Antidepressant use and colorectal cancer risk. Coogan PF, Strom BL, Rosenberg L. Slone Epidemiology Center at Boston University, Boston, MA, USA. PURPOSE: A previous epidemiologic study reported a 30% reduced risk of colorectal cancer among users of high doses of selective serotonin reuptake inhibitors (SSRIs). We assessed the association of colorectal cancer risk with SSRI and tricyclic antidepressant use in our hospital-based Case Control Surveillance Study. METHODS: For the SSRI analyses, we used data collected on 529 colorectal cancer cases and 1955 hospitalized controls collected from 1995 to 2008. For the tricyclic antidepressant analyses, we used data on 2889 cases and 7122 controls collected from 1976 to 2008. We used multivariable logistic regression analysis to evaluate the association of regular SSRI use and regular tricyclic antidepressant use (daily use for at least 3 continuous months) with colorectal cancer risk. RESULTS: The odds ratio for regular SSRI use was 0.55 (95% CI 0.35-0.88) and it did not differ by duration of use. The odds ratio was 0.47 (95% CI 0.26-0.85) for colon cancer and 0.72 (95% CI 0.37-1.41) for rectal cancer. The odds ratio for regular use of tricyclic antidepressants was 0.77 (95% CI 0.52-1.16) CONCLUSIONS: We found an association of reduced risk of colorectal cancer with regular use of SSRIs. In light of laboratory data indicating that SSRIs may inhibit colon cancer and one previous epidemiologic study that also observed a decreased risk, further investigation of the effect of SSRIs on the risk of colorectal cancer is warranted. Copyright (c) 2009 John Wiley & Sons, Ltd.